Skip to main content

Table 1 Demographic, clinical, and CMR data for the entire cohort, comparing subjects with and without left ventricular (LV) involvement at CMR

From: Left ventricular fibro-fatty replacement in arrhythmogenic right ventricular dysplasia/cardiomyopathy: prevalence, patterns, and association with arrhythmias

 

All (n = 73)

No LV Involvement (n = 36)

LV Involvement (n = 37)

p-value

Demographics and clinical data

 Age (years)

34.2 ± 13.5

34.8 ± 15.7

33.6 ± 11.2

0.81

 Male sex (%)

37 (50.7)

16 (44.4)

21 (56.8)

0.35

 Mutation positive (%)

35 (48.0)

17 (47.2)

18 (48.7)

1.00

  PKP2 (%)

30 (41.1)

17 (47.2)

13 (35.1)

0.39

  DSP (%)

1 (1.4)

0 (0)

1 (2.7)

  DSC2 (%)

0 (0)

0 (0)

0 (0)

  DSG2 (%)

1 (1.4)

0 (0)

1 (2.7)

  PLN (%)

1 (1.4)

0 (0)

1 (2.7)

  Compounda (%)

2 (2.7)

0 (0)

2 (5.4)

 Proband (%)

41 (56.2)

14 (39.0)

27 (73.0)

0.005

 TFC points

6 (IQR 5–7)

5 (IQR 4–6.5)

7 (IQR 5–8)

0.001

CMR findings

 RVEDVI (mL/m2)

106.7 ± 31.0

101.5 ± 26.1

111.9 ± 34.6

0.19

 RVEF (%)

41.7 ± 10.0

46.3 ± 8.7

37.2 ± 9.2

 < 0.001

 LVEDVI (mL/m2)

89.3 ± 19.8

87.9 ± 17.8

90.5 ± 21.6

0.45

 LVEF (%)

54.1 ± 6.6

57.9 ± 4.3

50.3 ± 6.5

 < 0.001

 RV-LGE (% with any RV LGE)

13 (17.8)

6 (16.7)

7 (18.9)

1.00

 RV Fat (% with any RV fat)

22 (30.1)

9 (25.0)

13 (35.1)

0.45

 RV-WMA (% with any RV WMA)

54 (74.0)

20 (55.6)

34 (91.9)

 < 0.001

  1. LV left ventricle, TFC task force criteria, CMR cardiovascular magnetic resonance imaging, RVEDVI right ventricular end-diastolic volume indexed to body surface area, RVEF right ventricular ejection fraction, LVEDVI LV end-diastolic volume indexed to body surface area, LVEF LV ejection fraction, RV-LGE right ventricular late gadolinium enhancement, RV fat right ventricular fat, RV-WMA right ventricular wall motion abnormality
  2. aOne patient had both a PKP2 and a DSP mutation. A second patient had two different DSG2 mutations in trans (compound heterozygous)